0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Treating a Patient with the Werner Syndrome and Osteoporosis Using Recombinant Human Insulin-like Growth Factor

Craig D. Rubin, MD; Berenice Reed, PhD; Khashayar Sakhaee, MD; and Charles Y. C. Pak, PhD
[+] Article and Author Information

From the University of Texas Southwestern Medical Center, Dallas, Texas. Requests for Reprints: Craig D. Rubin, MD, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-8889. Acknowledgments: The authors thank Dr. Neil Gesundheit and Genentech for providing the rhIGF-1; Beverley Adams-Huet for data management and analysis; and John Poindexter for technical support. Grant Support: By National Institutes of Health grants M01-RR00633 and R01-AR16061. Dr. Rubin is the recipient of Academic Award K08-AG00481 from the National Institute on Aging.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1994;121(9):665-668. doi:10.7326/0003-4819-121-9-199411010-00007
Text Size: A A A

Objective: To assess the safety and effect of recombinant human insulin-like growth factor 1 (rhIGF-1) on measures of bone metabolism in a human model of age-related osteoporosis.

Design: 6-month prospective case study.

Setting: General clinical research center.

Patients: 1 patient with the Werner syndrome, a low serum IGF-1 level, and osteoporosis.

Intervention: Daily subcutaneous administration of rhIGF-1 for 6 months.

Measurements: Serum alkaline phosphatase, osteocalcin, type I procollagen C-peptide and urinary hydroxyproline, calcium, and pyridinoline cross-links as measures of bone metabolism and radial shaft, femoral neck, and lumbar bone masses.

Results: Serum osteocalcin and type I procollagen C-peptide increased during rhIGF-1 therapy (P < 0.05). Twenty-four hour urinary calcium, hydroxyproline, and pyridinoline cross-links were also higher after treatment than they were before treatment (P < 0.05). During 6 months of treatment, the bone mineral density of the L2 to L4 vertebrae increased 3%; this value exceeded the coefficient of variation of this measurement. Bone density at the femoral neck and radial shaft changed by less than the coefficient of variation of these measurements. No significant changes in serum glucose values or other adverse effects of treatment were noted.

Conclusions: Treatment with rhIGF-1 increased both bone formation and resorption in a patient with the Werner syndrome, a low baseline serum IGF-1 level, and established osteoporosis. Because lumbar bone mass increased without evidence of bone loss in the appendicular skeleton, a net increase in bone formation (formation greater than resorption) may have been responsible.

Figures

Grahic Jump Location
Figure 1.
Serum insulin-like growth factor type 1 (IGF-1) and IGF-1-binding protein-3 (IGF-1-BP-3) levels before and during treatment with recombinant human IGF-1.

black circles = serum IGF-1 levels measured at baseline and during inpatient and outpatient evaluations throughout the study period. ▵ = serum IGF-1-BP-3 levels measured at baseline and at various times during the first 20 weeks of therapy (normal range, 2.28 to 5.25 mg/L). The height of the dotted area under the curve shows varying rhIGF-1 dosing at different points during the 26-week study and allows comparisons of dose, serum IGF-1 levels, and IGF-1-BP levels. All samples (except those from baseline evaluation) were taken immediately before the single daily administration of rhIGF-1.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)